Impact of atrial fibrillation on mortality, stroke, and medical costs

Archives of Internal Medicine

Volumn 158, Issue 3, 1998, Pages 229-234

  Wolf, Philip A ^a   Mitchell, Janet B ^c   Baker, Colin S ^c   Kannel, William B ^d   D'Agostino, Ralph B ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Boston University   (United States)

^c Health Economics Research Inc   (United States)

^d Natl Heart Lung/Blood Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COST BENEFIT ANALYSIS; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MEDICARE; MORTALITY; PREVENTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR; STROKE;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; CEREBROVASCULAR DISORDERS; HUMANS; LEAST-SQUARES ANALYSIS; MEDICARE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK; SEX DISTRIBUTION; TREATMENT OUTCOME; UNITED STATES;

EID: 0032498577     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.3.229     Document Type: Article

References (17)

1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med. 1995; 155:469-473.
2. Benjamin EJ, Levy D, D'Agostino RB, Belanger AJ, Wolf PA. Predictors of mortality following the onset of atrial fibrillation. Circulation. 1995;92:1-140. Abstract.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke. 1991;22:983-988.
4. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med. 1994;154:1449-1457.
5. European Atrial Fibrillation Trial Study Group (EAFT). Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255-1262.
6. Benjamin EJ, Levy D, D'Agostino RB, Belanger AJ, Wolf PA. Impact of atrial fibrillation on the risk of death: The Framingham Study. J Am Coll Cardiol. 1995; 25:230A. Abstract.
7. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation: The Framingham Study. Stroke. 1996;27:1760-1764.
8. Wolf PA, Benjamin EJ, Belanger AJ, Kannel WB, Levy D, D'Agostino RB. Secular trends in the prevalence of atrial fibrillation: The Framingham Study. Am Heart J. 1996;131:790-795.
9. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995;274:1839-1845.
10. International Classification of Diseases, Ninth Revision, Clinical Modification. Washington, DC: Public Health Service, US Dept of Health and Human Services; 1988.
11. Cox DR, Oakes D. Analysis of Survival Data. New York, NY: Chapman & Hall; 1984.
12. Halverson R, Palmquist R. The interpretation of dummy variables in semilogaritnmic equations. Am Econ Rev. 1980;70:474-475.
13. Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham Study. Neurology. 1978;28:973-977.
14. Wolf PA, Kannel WB, McGee DL, Meeks SL, Bharucha NE, McNamara PM. Duration of atrial fibrillation and imminence of stroke: The Framingham Study. Stroke. 1983;14:664-667.
15. McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett ELC. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med. 1995;155:277-281.
16. Liebson CL, Naessens JM, Brown RD, Whisnant JP. Accuracy of hospital discharge abstracts for identifying stroke. Stroke. 1994;25:2348-2355.
17. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort: The Framingham Heart Study. JAMA. 1994;271:840-844.